BioDelivery Sciences (BDSI) Signs a License Agreement with Shionogi to Commercialize Symproic (naldemedine) in the US

 BioDelivery Sciences (BDSI) Signs a License Agreement with Shionogi to Commercialize Symproic (naldemedine) in the US

BioDelivery Sciences (BDSI) Signs a License Agreement with Shionogi to Commercialize Symproic (naldemedine) in the US

Shots:

  • Shionogi to receive $30M upfront ($20M as initial payment & additional $10M in 6mos.) and royalties based on the sales of Symproic. BDSI to get exclusive commercialization rights for Shionogi’s Symproic (naldemedine, 0.2mg) in the US and Puerto Rico
  • The focus of the agreement is to strengthen the BDSI’s portfolio with expected company’s net sales $92-$100M and combined net sales of Belbuca and Symproic expected to be $325-$400M in H2’19
  • Symproic (naldemedine, 0.2mg) is indicated for opioid-induced constipation (OIC) in adults, being evaluated in seven P-III clinical studies and has received highest category of endorsement from the American Gastroenterological Association in patients with laxative-refractory OIC

Click here to read full press release/ article | Ref: BioDelivery | Image: WSJ

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post